Acceptability of a Bioadhesive Nonoxynol-9 Gel Delivered by an Applicator as a Rectal Microbicide

Authors:
  • CCConnie L. Celum
    Connie L. Celum
  • STStephen R. Tabet
    Stephen R. Tabet
  • CKClifton W. Kelly
    Clifton W. Kelly
  • ACAnne S. Coletti
    Anne S. Coletti
  • MCMargaret A. Chesney
    Margaret A. Chesney

Abstract
Potential rectal microbicides, as an adjunct to condoms for HIV/STD prevention, have not been studied previously. Advantage 24™ (1.5 ml of a bioadhesive gel containing 52.5 mg nonoxynol-9 administered by single-use applicator)-under investigation as a vaginal microbicide-was evaluated for acceptability among male couples. Twenty-five HIV-negative and 10 HIV-positive male couples participated in a frequency use escalation trial. Diaries and self-administered questionnaires assessed product use, acceptability, sexual behavior, and gastrointestinal and urologic side effects. Excluding participants who felt no need for an HIV prevention method, 58% said they would use Advantage 24 if approved for rectal use; 69% of receptive users reported rectal fullness and related side effects after insertion of the gel, and 68% reported applicator-related discomfort; 59% of insertive participants found the gel too sticky. Acceptability remains inconclusive and warrants further study of redesigned applicators and ways to minimize rectal side effects.

This publication has 12 references indexed in Scilit: